ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2790

CMR with Quantitative T2 Mapping in Patients with Active SLE

Stacy P. Ardoin1, Wael N. Jarjour2, Subha V. Raman2, Amanda Kibler2 and Tam Tran2, 1Pediatric & Adult Rheumatology, Ohio State University College of Medicine, Columbus, OH, 2Ohio State University, Columbus, OH

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: MRI, SLE and cardiovascular disease

  • Tweet
  • Email
  • Print
Session Information

Title: 2014 Rheumatology Research Foundation Edmond L. Dubois, MD Memorial Lectureship

Session Type: Abstract Submissions (ACR)

Background/Purpose:   Cardiovascular (CV) disease is an important cause of morbidity in systemic lupus erythematosus (SLE) .  Myocarditis is considered an uncommon complication of SLE but autopsy studies suggest prevalence of up to 40%.  With this study we used cardiac magenetic resonance (CMR) quantitative T2 mapping to assess for subclinical myocardial involvement during SLE flare.  

Methods:   Consecutive patients with active SLE (defined by SLEDAI > 5 and clinician’s intention to change therapy due to disease activity) without bias to CV symptoms were enrolled at a single academic center.  Clinical, demographic and laboratory data were collected. CMR was performed on 1.5 Tesla scanner and included cine imaging, T2 mapping in long and short axes. Late gadolinium enhancement was assessed after contrast administration if GFR > 30.  Left ventricular (LV) end diastolic volumes, end systolic mass and peak circumferential strain were measured.  All images were scored by an experienced, blinded reader.  To reduce artifactual findings, T2 mapping was limited to the 6 mid cardiac segments, and involvement of ≥2 mid-segments was considered abnormal. Based upon myocarditis literature, T2 scores > 59 ms were considered abnormal. Descriptive statistics were performed; means were compared using Student’s t-test and correlation assessed with Pearsons’ coefficient.

Results:   27 patients underwent CMR: mean age 32.4 years, 82% female, 44% black, mean SLEDAI-2K 10.4, mean SLICC DI 0.52 (see Table 1).  12/27 (44%) of patients had ≥ 2 mid cardiac segments with elevated T2 signal (Table 2). The mean T2 signal for mid cardiac segments was elevated compared to 40 historical healthy controls (57.0 ms ± 5 vs. 54.5 ms ± 2.2; p= 0.010)   The mean LV circumferential strain was -15.2% ± 5.4 which is lower than accepted normal values (-20%).  SLEDAI-2K scores positively correlated with mean mid cardiac T2 signal (r = 0.57); and mid cardiac maximum T2 signal (r = 0.65). Only 2/27 (7%) patients had positive LGE.

Conclusion: In this cohort of active SLE patients, CMR with quantitative T2 mapping identified a high prevalence (44%) of patients with abnormal T2 signal in ≥2 mid cardiac segments, suggesting subclinical myocardial inflammation may be common in SLE flare. Both mean and max mid segment T2 showed correlation with SLE disease activity measured by SLEDAI scores.  Mean LV circumferential strain was lower than normal, suggesting impaired LV function.  Very few CMR showed evidence of myocardial fibrosis as measured by LGE enhancement. Further study is needed to determine if abnormal quantitative T2 mapping during SLE flare foreshadows longer term CV complications.  

Table 1:  Patient Characteristics

Age, mean ± SD years

32.4 ± 9.7

Female, no. (%)

22 (82%)

Black/White/Other, no. (%)

12 (44%), 11 (41%), 4 (15%)

Hispanic, no. (%)

2 (7%)

History of hypertension, no. (%)

9 (33%)

History of hyperlipidemia, no. (%)

6 (22%)

History of myocardial infarction, no. (%)

0

History of ischemic stroke, no. (%)

3 (11%)

History of congestive heart failure, no. (%)

0

Current/former smoker, no. (%)

9 (33%)

Anti-phospholipid antibody positive, no. (%)

6 (22%)

Anti-phospholipid antibody syndrome, no. (%)

1 (4%)

SLEDAI-2K score, mean ± SD

10.4 ± 6.3

SLICC Damage Index, mean ± SD

0.5 ± 0.77

Troponin I, mean ±, ng/mL

0.057 ± 0.009

CK, mean ± SD, U/L

146.8 ±500.6

C-reactive protein ± mg/L

25.6 ±16.1

 

Table 2: CMR Findings in Patients with Active SLE

≥ 2 mid segments with T2 >59 ms, no. (%)

12 (44%)

Mean mid segment T2, mean ± ms

57.2 ± 5.0

Peak mid segment  T2, mean ± ms

63.0 ± 7.7

Heart rate, mean ±SD

78.4 ± 16.0

LV end diastolic volume, mean ±SD

147.9 ± 35.5

LV end systolic volume, mean ±SD

61.9 ± 30.7

LV ejection fraction, mean  ± SD, %

0.60 ± 0.10

LV mass, mean ± SD

86.5 ±29.6


Disclosure:

S. P. Ardoin,
None;

W. N. Jarjour,
None;

S. V. Raman,
None;

A. Kibler,
None;

T. Tran,
None.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cmr-with-quantitative-t2-mapping-in-patients-with-active-sle/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology